These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 991456)

  • 1. Inhibition of complement-dependent lymphocyte rosette formation by sera of patients with chronic glomerulonephritis.
    Gluckman JC; Beaufils H; Sanchez F
    Clin Exp Immunol; 1976 Nov; 26(2):247-52. PubMed ID: 991456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The inhibition of complement-dependent lymphocyte rosette formation by the sera of children with steroid-sensitive hephrotic syndrome and other renal diseases.
    Smith MD; Barratt TM; Hayward AR; Soothill JF
    Clin Exp Immunol; 1975 Aug; 21(2):236-43. PubMed ID: 1183072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
    Perrin LH; Lambert PH; Miescher PA
    J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum-mediated inhibition of lymphocyte Fc gamma receptors in glomerulonephritis.
    Bakkaloglu A; Sandilands GP; Briggs JD; Anderson JR
    Clin Exp Immunol; 1980 Dec; 42(3):490-4. PubMed ID: 6111406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of the material inhibiting EAC-rosette formation in the sera of patients with nephropathies.
    Smith MD; Verroust PJ; Adam C; Galceran M; Morel-Maroger L
    Clin Exp Immunol; 1977 Dec; 30(3):364-9. PubMed ID: 606450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of C3 rosette formation by serum from patients with systemic lupus erythematosus. A corollary of disease activity.
    Scheinberg MA; Israel Filho G; Mendes NF; Vertzman L
    J Rheumatol; 1978; 5(1):19-25. PubMed ID: 305960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Specific measurement of alternate pathway activation of complement in human glomerulonephritides (GN): 125 cases (author's transl)].
    Berthoux FC; Freyria AM
    Nephrologie; 1980; 1(2):61-6. PubMed ID: 7301022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum and glomerular complement in 205 cases of glomerulonephritis.
    Durante A; Rovati C; di Belgiojoso GB; Minetti L
    Proc Eur Dial Transplant Assoc; 1976; 12():189-96. PubMed ID: 935112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of circulating immune complexes detection in chronic glomerulonephritis.
    Gluckman JC; Jacob N; Beaufils H; Baumelou A; Salah H; German A; Legrain M
    Nephron; 1978; 22(1-3):138-45. PubMed ID: 370624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.
    Ross GD; Yount WJ; Walport MJ; Winfield JB; Parker CJ; Fuller CR; Taylor RP; Myones BL; Lachmann PJ
    J Immunol; 1985 Sep; 135(3):2005-14. PubMed ID: 4020137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease activity in the nephritis of systemic lupus erythematosus in relation to serum complement concentrations. DNA-binding capacity and precipitating anti-DNA antibody.
    Cameron JS; Lessof MH; Ogg CS; Williams BD; Williams DG
    Clin Exp Immunol; 1976 Sep; 25(3):418-27. PubMed ID: 1085678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppressive activity of serum lipoproteins from patients with idiopathic nephrotic syndrome.
    Inoue K; Yamashita U; Yamashita F
    Jpn J Exp Med; 1984 Apr; 54(2):73-80. PubMed ID: 6471527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clearances of complement components, C3 proactivator and other serum proteins in chronic membranoproliferative glomerulonephritis (CMPGN).
    Geiger H; Good RA; Day NK
    Clin Nephrol; 1975; 3(4):139-47. PubMed ID: 1149337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of circulating soluble immune complexes in patients with various renal diseases.
    Stühlinger WD; Verroust PJ; Morel-Maroger L
    Immunology; 1976 Jan; 30(1):43-7. PubMed ID: 1248861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Terminal complement complex in plasma from patients with systemic lupus erythematosus and other glomerular diseases.
    Horigome I; Seino J; Sudo K; Kinoshita Y; Saito T; Yoshinaga K
    Clin Exp Immunol; 1987 Nov; 70(2):417-24. PubMed ID: 3427827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study of B-lymphocytes with receptors to C3 component of complement in patients with glomerulonephritis and systemic lupus erythematosus].
    Gordovskaia NB; Bulanova TD; Traianova TG
    Ter Arkh; 1977; 49(7):45-50. PubMed ID: 331546
    [No Abstract]   [Full Text] [Related]  

  • 17. Lymphocytotoxic activity in primary glomerulonephritis: evidence for immune complex-mediated cytotoxicity.
    Charlesworth JA; Bowman C; Perl SI; Yasmeen D; Pussell BA
    J Clin Lab Immunol; 1981 Nov; 6(3):233-6. PubMed ID: 6978404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition by C3 fragments of C3-dependent rosette formation and antigen-induced lymphocyte transformation.
    Pepys MB; Butterworth AE
    Clin Exp Immunol; 1974 Oct; 18(2):273-82. PubMed ID: 4619599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement-mediated solubilization of immune complexes in systemic lupus erythematosus.
    Sakurai T; Fujita T; Kono I; Kabashima T; Yamane K; Tamura N; Kashiwagi H
    Clin Exp Immunol; 1982 Apr; 48(1):37-42. PubMed ID: 6979449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement-mediated inhibition of immune precipitation in patients with immune complex diseases.
    Naama JK; Mitchell WS; Zoma A; Veitch J; Whaley K
    Clin Exp Immunol; 1983 Feb; 51(2):292-8. PubMed ID: 6220848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.